# Kinnate Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kinnate-biopharma

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.kinnate.com
- Total disclosed funding: $163M
- Latest round: Series C (Jul 21, 2020)
- Investors on record: 14

## About

Based in California, US, and founded in 2018 by CEO Nima Farzan, Kinnate Biopharma, Inc. operates as a clinical-stage precision oncology company providing cancer treatments. In February 2024, XOMA Corporation agreed to acquire Kinnate Biopharma, Inc. 

Kinnate Biopharma, Inc. developed a pipeline of small molecule drug candidates through its Kinnate Discovery Engine. It offers two main clinical programs targeting solid tumors with RAF, NRAS, and FGFR-driven alterations. The company's lead product candidates include exarafenib, an investigational pan-RAF inhibitor for cancers with BRAF and NRAS mutations, and KIN-3248, an investigational FGFR inhibitor targeting cancers with FGFR2 and FGFR3 alterations. In addition, the firm provides early-stage programs including c-MET inhibitor designed to target resistant variants and a brain-penetrant CDK4 selective inhibitor program.

## Funding rounds

- Series C, Jul 21, 2020, $88M — OrbiMed Advisors, Viking Global Investors, Nextech, Fidelity Investments, Tavistock Group, Foresite Capital, RA Capital Management, Vida Ventures, Janus Henderson Investors, Surveyor Capital, SVB Leerink, Logos Capital, Venrock Healthcare Capital Partners
- Series B, Dec 19, 2019, $75M — OrbiMed Advisors, Nextech, Foresite Capital, Eshelman Ventures, Vida Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B, Series C
- Eshelman Ventures (https://capitalatlas.ai/funds/eshelman-ventures) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B, Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Janus Henderson Investors — Series C
- Surveyor Capital — Series C
- SVB Leerink — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series C